Phase 2 of Neovasc's TIARA-II Study to Commence in Germany and the United Kingdom


January 29, 2019—Neovasc Inc. announced that it has completed the phase 1 requirements of the TIARA-II study required by the biphasic study design in both Germany and the United Kingdom. The company has received approval to proceed with phase 2 of the TIARA-II study for its Tiara transcatheter mitral valve replacement device. The approval will allow the TIARA-II study to proceed in these geographies with no restrictions.

According to the company, this approval comes after adjudication of adverse events by the Clinical Events Committee as well as Data and Safety Monitoring Board review of the data, and governmental regulatory and ethics committee reviews of the interim clinical report provided for 20 patients receiving implants.

The TIARA-II study is an international, multicenter, single-arm, prospective, nonrandomized, safety and performance clinical study. The total enrollment goal for the study in all geographies is 115 implanted subjects.

Tiara is a self-expanding mitral bioprosthesis designed to treat mitral valve regurgitation by replacing the diseased valve. The Tiara valve is currently being evaluated in the TIARA I early feasibility trial in the United States, Canada, and Belgium, and in the TIARA II European CE Mark trial in Germany, Italy, and the United Kingdom.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.